HydRegen
- 27/04/2023
- Unknown
- $3,242,000
Our biotechnologies enable more sustainable chemical synthesis and manufacturing by replacing toxic, heavy-metal catalysts, operating under mild reaction conditions, minimising waste and operating in continuous flow.
HydRegen is a spinout company from the Department of Chemistry (University of Oxford), commercialising a biotechnology from the group of Prof. Kylie Vincent.
- Industry Biotechnology
- Website https://hydregenoxford.com/
- LinkedIn https://www.linkedin.com/company/hydregen/
Related People
Holly ReeveCo Founder
I am a researcher entrepreneur, committed to using lessons from nature to tackle challenges in chemical manufacturing. As CEO of HydRegen, my vision is to see our pioneering biocatalysis technology used to enable a more sustainable chemicals sector, alongside creating an inclusive and balanced company culture where individuals are working towards personal and company goals.
From 2016, I lead a research program taking a biotechnology, HydRegen, from proof-of-concept results to commercial offering as a spinout in 2021. The technology simplifies use of biocatalysis in chemical manufacturing, allowing isolated enzymes to be handled in the same was as supported metal catalysts for hydrogenation reactions. Recognising trends in translating heterogeneous hydrogenation chemistry into continuous flow reactors, we successfully implemented HydRegen in an industry-standard hydrogenation flow reactor. This, along with other key development highlights, have been critical to chemists recognising the potential of HydRegen as a 'slot-in' alternative to metal-catalysts for sustainable processes across the chemicals sector.